Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Infection Clear all
Completed Phase 1 Interventional

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

NCT00002946
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
penclomedine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00058292
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Echo vs. EGDT in Severe Sepsis and Septic Shock

NCT02354742
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Echo guided fluid resuscitation, EGDT fluid resuscitation
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional Results available

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

NCT04347226
View directory record Official record
Conditions
Solid Tumor, Sars-CoV2, Hematological Malignancy
Interventions
BMS-986253
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

NCT04486625
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Aztreonam-Avibactam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

NCT00361049
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
Biological · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT06685835
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis

NCT02432807
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vancomycin 1.1%, Placebo
Drug
Lead sponsor
Kurobe LLC
Industry
Eligibility
1 Year and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
16
States / cities
Paramount, California • Petaluma, California • Rancho Cordova, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 27, 2026, 5:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Measurement of Reactive Hyperemia in Critical Care

NCT01726595
View directory record Official record
Conditions
Severe Sepsis, Critical Illness
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC

NCT00000680
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Early Phase 1 Interventional

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

NCT03099980
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents

NCT05252910
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Pharm-Olam, LLC
Industry
Eligibility
12 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Boston, Massachusetts • Omaha, Nebraska • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

NCT05011513
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
78
States / cities
Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00004192
View directory record Official record
Conditions
Lymphoma, Neutropenia
Interventions
filgrastim, pegfilgrastim, cisplatin, cytarabine, etoposide, methylprednisolone
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections

NCT00001911
View directory record Official record
Conditions
Atypical Mycobacterium Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated No phase listed Observational

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT00651716
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
flow cytometry, laboratory biomarker analysis, Data Collection
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 27, 2026, 5:55 PM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 3 Interventional

Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

NCT04412772
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional Results available

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View directory record Official record
Conditions
COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

NCT05092581
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Stony Brook, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

NCT00072514
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
gemcitabine hydrochloride, carboplatin, dexamethasone, rituximab
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 27, 2026, 5:55 PM EDT